Interaction of MRE11 and Clinicopathologic Characteristics in Recurrence of Breast Cancer: Individual and Cumulated Receiver Operating Characteristic Analyses

Abstract

The interaction between the meiotic recombination 11 homolog A (MRE11) oncoprotein and breast cancer recurrence status remains unclear. The aim of this study was to assess the interaction between MRE11 and clinicopathologic variables in breast cancer. A dataset for 254 subjects with breast cancer (220 nonrecurrent and 34 recurrent) was used in individual and cumulated receiver operating characteristic (ROC) analyses of MRE11 and 12 clinicopathologic variables for predicting breast cancer recurrence. In individual ROC analysis, the area under curve (AUC) for each predictor of breast cancer recurrence was smaller than 0.7. In cumulated ROC analysis, however, the AUC value for each predictor improved. Ten relevant variables in breast cancer recurrence were used to find the optimal prognostic indicators. The presence of any six of the following ten variables had a high (79%) sensitivity and a high (70%) specificity for predicting breast cancer recurrence: tumor size ≥ 2.4 cm, tumor stage II/III, therapy other than hormone therapy, age ≥ 52 years, MRE11 positive cells > 50%, body mass index ≥ 24, lymph node metastasis, positivity for progesterone receptor, positivity for epidermal growth factor receptor, and negativity for estrogen receptor. In conclusion, this study revealed that these 10 clinicopathologic variables are the minimum discriminators needed for optimal discriminant effectiveness in predicting breast cancer recurrence.

Elevated MRE11 expression associated with progression and poor outcome in prostate cancer

“…Relatively, heterozygous mutation only contributes a limited fraction of tumorigenesis, and aberrant molecular variation of MRN is more frequent and of great clinical significance 21, 22. Previous studies had reported the role of MRE11 in cell survival and proliferation 23, and malignant cancer behavior was significantly correlated with elevated MRE11 expression phenotypes in breast 19, 24, 25, gastric 26 and rectal cancer 27, 28. Similarly, it was noteworthy that increased recurrence rate and chemoresistance of certain cancers correlated with high expression level of MRN complex 28-30.…”

Cumulative receiver operating characteristics for analyzing interaction between tissue visfatin and clinicopathologic factors in breast cancer progression

“…ROC analysis is also used to evaluate the accuracy of various biomarkers for diagnosis, prognosis and survival predictions for cancer patients [ 24 – 31 ]. Recently, ROC analysis has been improved by simultaneously considering multiple factors in terms of cumulative ROC analysis [ 32 – 34 ].…”